GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Huaren Pharmaceutical Co Ltd (SZSE:300110) » Definitions » EV-to-EBIT

Huaren Pharmaceutical Co (SZSE:300110) EV-to-EBIT : 18.51 (As of May. 29, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Huaren Pharmaceutical Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Huaren Pharmaceutical Co's Enterprise Value is ¥5,617 Mil. Huaren Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ¥303 Mil. Therefore, Huaren Pharmaceutical Co's EV-to-EBIT for today is 18.51.

The historical rank and industry rank for Huaren Pharmaceutical Co's EV-to-EBIT or its related term are showing as below:

SZSE:300110' s EV-to-EBIT Range Over the Past 10 Years
Min: 18.32   Med: 54.8   Max: 249.66
Current: 18.43

During the past 13 years, the highest EV-to-EBIT of Huaren Pharmaceutical Co was 249.66. The lowest was 18.32. And the median was 54.80.

SZSE:300110's EV-to-EBIT is ranked worse than
54.34% of 668 companies
in the Drug Manufacturers industry
Industry Median: 16.885 vs SZSE:300110: 18.43

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Huaren Pharmaceutical Co's Enterprise Value for the quarter that ended in Mar. 2024 was ¥5,880 Mil. Huaren Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ¥303 Mil. Huaren Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 5.16%.


Huaren Pharmaceutical Co EV-to-EBIT Historical Data

The historical data trend for Huaren Pharmaceutical Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Huaren Pharmaceutical Co EV-to-EBIT Chart

Huaren Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 54.41 48.71 34.49 25.12 22.98

Huaren Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.57 24.30 24.59 22.98 19.38

Competitive Comparison of Huaren Pharmaceutical Co's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Huaren Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Huaren Pharmaceutical Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Huaren Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Huaren Pharmaceutical Co's EV-to-EBIT falls into.



Huaren Pharmaceutical Co EV-to-EBIT Calculation

Huaren Pharmaceutical Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=5617.043/303.463
=18.51

Huaren Pharmaceutical Co's current Enterprise Value is ¥5,617 Mil.
Huaren Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥303 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Huaren Pharmaceutical Co  (SZSE:300110) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Huaren Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=303.463/5879.6048
=5.16 %

Huaren Pharmaceutical Co's Enterprise Value for the quarter that ended in Mar. 2024 was ¥5,880 Mil.
Huaren Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥303 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Huaren Pharmaceutical Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Huaren Pharmaceutical Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Huaren Pharmaceutical Co (SZSE:300110) Business Description

Traded in Other Exchanges
N/A
Address
No. 187 Zhuzhou Road, Qingdao, Shandong, CHN, 266100
Huaren Pharmaceutical Co Ltd is a China-based company engaged in the manufacture, and sale of non-polyvinyl chloride and Non-PVC large capacity preparations. Its categories of products include conventional infusion, therapy infusion, and nutrition infusion. The company distributes its products in domestic market, with Northeast China as its main market.
Executives
Yang Xiao Dong Director
Bo Guo Xiu Executives
Zhou Xi Jian Director
Mao Yu Wei Supervisors
Chu Xiao Jun Executives
Zhou Qiang Directors, executives
Ji Sheng Bin Executives
Xiao Wei Wen Executives
Shen Hong Ce Executives
Li Xiao Li Executives
Liu Qian Executives
Wang Wen Ping Executives
Liang Fu You Director
Liang Fu Dong Director
Gong Ling Secretary Dong

Huaren Pharmaceutical Co (SZSE:300110) Headlines

No Headlines